[stock_market_widget type=”card” template=”basic2″ assets=”NRXS” realtime=”true” api=”yahoo-finance”]
Functional abdominal pain tied to irritable bowel syndrome affects a meaningful share of children and teenagers, and for years the treatment options were limited to dietary adjustments, talk therapy, or medications that were never designed for young patients. Neuromodulation, a category of therapy that uses gentle electrical stimulation to interrupt pain signals traveling between the gut and the brain, has slowly moved from an experimental idea into something insurers are willing to pay for. The approach appeals to physicians who are cautious about prescribing drugs to children for a condition that has no FDA approved medication.
The device most closely associated with this shift is Percutaneous Electrical Nerve Field Stimulation, often shortened to PENFS. It works by stimulating cranial nerve bundles located in the ear, a method that sounds unusual but has built up enough clinical evidence to earn its own Category I CPT code, effective January 1, 2026. That code matters more than it might seem. Without a standard billing code, insurers tend to treat a therapy as experimental and decline to cover it. With one in place, physicians can bill more predictably, and health plans have a clearer path to writing coverage policies. That single change has quietly reshaped the commercial prospects for companies making these devices. Before the code existed, a family seeking this kind of treatment often paid out of pocket or relied on patient assistance programs, which slowed adoption even when physicians believed the therapy could help. Coverage decisions, not clinical breakthroughs alone, tend to determine how quickly a device like this reaches the patients who might benefit from it.
NeurAxis, Inc. (NYSE American: NRXS) is one of the companies benefiting from that shift. The Carmel, Indiana based medical technology company makes IB Stim, a non invasive PENFS device that is FDA cleared for functional abdominal pain associated with irritable bowel syndrome and functional dyspepsia in patients age 8 and older. The company has announced that a major national health insurer had added medical policy coverage for PENFS across multiple states, extending access to approximately 18 million additional health plan members. That single deal brings the total number of covered lives for the therapy to more than 120 million people in the United States, according to the company.
Brian Carrico, the company’s chief executive officer, said the milestone reflects years of work translating clinical publications into insurance policy decisions, and he pointed to ongoing conversations with other national insurers as evidence that the pace of coverage gains should continue. For a company of NeurAxis’s size, that kind of reimbursement progress carries outsized weight because it does not depend on the binary outcome of a late stage drug trial, the kind of event that can send a small stock soaring or collapsing overnight.
Investors have shown a tendency to reward these incremental coverage announcements. When NeurAxis disclosed a smaller payer expansion covering roughly 500,000 members on August 4, 2026, shares rose 6.37% in a single trading session. That reaction offers a rough benchmark for how the market might respond to the latest, much larger announcement, though past price moves are never a guarantee of future ones. The company’s second quarter 2026 results, reported in August, already showed revenue climbing 116% from a year earlier to $1.93 million, a jump the company attributed largely to the new CPT code and expanding coverage.
NeurAxis remains a micro cap company, and its revenue base is still small relative to the U.S. healthcare market as a whole. But the pattern taking shape, steady payer additions building on a foundation of clinical guidelines and a recognized billing code, gives the business a growth path that looks less like a lottery ticket and more like a slow accumulation of institutional trust. Whether that trust eventually translates into meaningfully larger revenue will depend on how many of the remaining major national insurers follow the same path toward coverage. For now, each new policy announcement adds another piece to that picture, one health plan at a time.
